Related Experiment Video

Updated: Aug 13, 2026

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

The role of tirofiban in acute coronary syndromes

A Gomma1, J Collinson, H Purcell

  • 1Department of Cardiology and Clinical Trials, Royal Brompton Hospital, London.

International Journal of Clinical Practice
|May 29, 2000
PubMed

Insights

Tirofiban, a glycoprotein IIb/IIIa inhibitor, effectively reduces ischemic complications in acute coronary syndromes (ACS) when combined with aspirin and heparin. This therapy is well-tolerated in high-risk patients undergoing revascularization.

Area of Science:

  • Cardiology
  • Pharmacology
  • Thrombosis Research

Background:

  • Platelet activation and aggregation are crucial in forming intracoronary thrombus during acute coronary syndromes (ACS).
  • Despite current therapies like aspirin and heparin, ACS continues to have high morbidity and mortality rates.
  • Glycoprotein IIb/IIIa receptor inhibitors offer a targeted approach by blocking the final common pathway of platelet aggregation.

Purpose of the Study:

  • To evaluate the efficacy and safety of tirofiban, a specific glycoprotein IIb/IIIa receptor inhibitor, in patients with ACS.
  • To assess the role of tirofiban in reducing ischemic complications in various high-risk cardiovascular patient populations.

Main Methods:

  • Analysis of data from three major international clinical trials (PRISM, PRISM-PLUS, RESTORE) involving over 7200 patients.
  • Tirofiban administered in combination with standard therapy (aspirin and heparin).
  • Evaluation of ischemic complications in patients with unstable angina, non-Q-wave myocardial infarction, and those undergoing revascularization.

Main Results:

  • Tirofiban demonstrated good tolerability in clinical trials.
  • Combination therapy with tirofiban, aspirin, and heparin significantly reduced the risk of ischemic complications.
  • The benefits were observed across different ACS patient subgroups, including those undergoing revascularization.

Conclusions:

  • Tirofiban is an effective and well-tolerated treatment option for managing ACS.
  • Glycoprotein IIb/IIIa inhibition with tirofiban represents a valuable strategy in preventing thrombotic events in high-risk cardiovascular patients.
  • Ongoing studies continue to explore the full potential of tirofiban in cardiovascular medicine.

More Related Videos

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Microfluidics in Assessing Platelet Function06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...